MedPath

Dual-layer spectral computerized tomography for breast cancer detection in women with dense breasts: a single centre, feasibility study.

Recruiting
Conditions
10006232
Mammary cancer
10006291
Registration Number
NL-OMON50792
Lead Sponsor
Rijnstate Ziekenhuis
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
Recruiting
Sex
Not specified
Target Recruitment
14
Inclusion Criteria

1. Females aged 18 years and over
2. Diagnosis of histopathologically proven locoregional advanced primary breast
cancer:
- A. Tumors > 5 cm (= T3) or
- B. Tumors with invasion of the skin or chest wall (= T4) or
- C. Any tumor with >= 4 axillary lymph nodes or ipsilateral internal mammary,
infraclavicular or supraclavicular nodal involvement (= N2-3)
3. Heterogeneously or extremely dense breasts on full-field digital mammograms:
category C or D according to the ACR BI-RADS lexicon

Exclusion Criteria

1. History of allergic reactions to iodinated contrast agents
2. Pregnancy or breast feeding
3. Treatment of thyroid disease with radioactive iodine
4. Use of metformin
5. Creatinine clearance < 45 ml/min
6. Chronic or acutely worsening renal disease

Study & Design

Study Type
Observational invasive
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
<p>To determine the feasibility of DLSCT to detect breast cancer in women with<br /><br>dense breasts and histopathologically locoregional advanced primary breast<br /><br>cancer.</p><br>
Secondary Outcome Measures
NameTimeMethod
<p>1. To determine iodine enhancement (HU) and iodine content (mg/mL) values of<br />tumor, normal breast tissue and pectoralis muscle in reconstructed virtual<br />monochromatic images obtained at 40, 60, 80 and 100 keV and iodine maps<br />2. To correlate tumor conspicuity and BI-RADS score with the following<br />features: size of tumor, type of tumor, MRI and PET-CT images, histologic<br />gradation of tumor and immunohistochemical staining results</p>
© Copyright 2025. All Rights Reserved by MedPath